Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2011

01-11-2011 | Original Article

Is Subdivision of pT2 Tumors Superior to Lymph Node Metastasis for Predicting Survival of Patients with Gastric Cancer? Review of 224 Patients from Four Centers

Authors: Ahmet Bilici, Faysal Dane, Mesut Seker, Bala Basak Oven Ustaalioglu, Mehmet Aliustaoglu, Suleyman Temiz, Cem Gezen, Dilek Yavuzer, Gorkem Aksu, Alpaslan Mayadagli, Mahmut Gumus, Kazim Uygun, Nazim Serdar Turhal

Published in: Digestive Diseases and Sciences | Issue 11/2011

Login to get access

Abstract

Background

The prognostic significance of the subclassification of pT2 tumors and the association of these categories with other clinicopathological factors in gastric cancer patients were investigated.

Methods

A total of 224 patients with pT2 gastric cancer who had undergone curative gastrectomy and lymph node dissection were retrospectively analyzed. The prognostic role of the subclassification of pT2 tumors was evaluated by univariate and multivariate analysis.

Results

Of 224 patients, 75 (33.5%) were classified as having pT2a tumors and 149 (66.5%) as having pT2b tumors. The prevalence of large-sized tumors (P < 0.003), lymph node involvement (P < 0.018), and lymphatic (P = 0.016), blood vessel (P = 0.001), and perineural invasion (P = 0.001) was significantly higher for pT2b tumors than for pT2a tumors. The rate of recurrence for pT2a cancers was significantly lower than that for pT2b cancers (P = 0.001).Median overall survival (OS) times and three-year OS of patients with a pT2b tumor were significantly worse than for patients with a pT2a tumor (P < 0.001).When patients were analyzed according to lymph node involvement, the prognosis of patients with pT2aN1 cancers was significantly better than that of patients with pT2bN1 (P < 0.001). Multivariate analysis indicated that the pT2 subdivision was an independent prognostic factor for OS (P = 0.006), as were pN stage, clinical stage, and recurrence.

Conclusion

Our results showed that subclassification of pT2 tumors into pT2a or pT2b was an important prognostic indicator for patients with pT2 gastric cancers who underwent curative gastrectomy. In the TNM staging system, subdivision of pT2 tumors should be undertaken routinely to detect gastric cancer patients who have a poor prognosis and to define patients more accurately in terms of their mortality after curative resection in accordance with the new 2010 AJCC TNM staging classification. This may also help as a guide to more appropriate therapy for tumors with subserosal invasion (old pT2b or new pT3).
Literature
1.
2.
go back to reference Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer. 2004;7:196–201.PubMedCrossRef Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 20 years. Gastric Cancer. 2004;7:196–201.PubMedCrossRef
3.
go back to reference Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–461.PubMedCrossRef Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449–461.PubMedCrossRef
5.
go back to reference Kim JG, Sohn SK, Chae YS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18:1030–1036.PubMedCrossRef Kim JG, Sohn SK, Chae YS, et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol. 2007;18:1030–1036.PubMedCrossRef
6.
go back to reference Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
7.
go back to reference Sarela AI, Turnbull AD, Coit DG, Klimstra D, Brennan MF, Karpeh MS. Accurate lymph node staging is of greater prognostic importance than subclassification of the T2 category for gastric adenocarcinoma. Ann Surg Oncol. 2003;10:783–791.PubMedCrossRef Sarela AI, Turnbull AD, Coit DG, Klimstra D, Brennan MF, Karpeh MS. Accurate lymph node staging is of greater prognostic importance than subclassification of the T2 category for gastric adenocarcinoma. Ann Surg Oncol. 2003;10:783–791.PubMedCrossRef
8.
go back to reference Komatsu S, Ichikawa D, Kurioka H, Kan K, et al. Prognostic and clinical evaluation of patients with T2 gastric cancer. Hepatogastroenterology. 2005;52:965–968.PubMed Komatsu S, Ichikawa D, Kurioka H, Kan K, et al. Prognostic and clinical evaluation of patients with T2 gastric cancer. Hepatogastroenterology. 2005;52:965–968.PubMed
9.
go back to reference Park do J, Kong SH, Lee HJ, et al. Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery. 2007;141:757–763.PubMedCrossRef Park do J, Kong SH, Lee HJ, et al. Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery. 2007;141:757–763.PubMedCrossRef
10.
go back to reference Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96:398–404.PubMedCrossRef Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96:398–404.PubMedCrossRef
11.
go back to reference Isozaki H, Fujii K, Nomura E, Mabuchi H, et al. Prognostic factors of advanced gastric carcinoma without serosal invasion (pT2 gastric carcinoma). Hepatogastroenterology. 1999;46:2669–2672.PubMed Isozaki H, Fujii K, Nomura E, Mabuchi H, et al. Prognostic factors of advanced gastric carcinoma without serosal invasion (pT2 gastric carcinoma). Hepatogastroenterology. 1999;46:2669–2672.PubMed
12.
go back to reference AJCC (American Joint Committee on Cancer). In: Edge SB, Byrd DR, Compton CC, et al., eds. Cancer Staging Manual. 7th ed. New York: Springer; 2010: 117. AJCC (American Joint Committee on Cancer). In: Edge SB, Byrd DR, Compton CC, et al., eds. Cancer Staging Manual. 7th ed. New York: Springer; 2010: 117.
13.
go back to reference Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998; 1: 10–24. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer 1998; 1: 10–24.
14.
go back to reference Lu Y, Liu C, Zhang R, Li H, et al. Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients. Surg Oncol. 2008;17:317–322.PubMedCrossRef Lu Y, Liu C, Zhang R, Li H, et al. Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients. Surg Oncol. 2008;17:317–322.PubMedCrossRef
15.
go back to reference Fotia G, Marrelli D, De Stefano A, Pinto E, Roviello F. Factors influencing outcome in gastric cancer involving muscularis and subserosal layer. Eur J Surg Oncol. 2004;30:930–934.PubMedCrossRef Fotia G, Marrelli D, De Stefano A, Pinto E, Roviello F. Factors influencing outcome in gastric cancer involving muscularis and subserosal layer. Eur J Surg Oncol. 2004;30:930–934.PubMedCrossRef
16.
go back to reference Okuno K, Shigeoka H, Tanaka A, Hirai N, Matsumura E, Yasutomi M. Clinicopathological evaluation of T2-gastric cancer among age groups. Hepatogastroenterology. 2000;47:1180–1182.PubMed Okuno K, Shigeoka H, Tanaka A, Hirai N, Matsumura E, Yasutomi M. Clinicopathological evaluation of T2-gastric cancer among age groups. Hepatogastroenterology. 2000;47:1180–1182.PubMed
17.
go back to reference Maehara Y, Anai H, Moriguchi S, Watanabe A, Tsujitani S, Sugimachi K. Gastric carcinoma invading muscularis propria and macroscopic appearance. Eur J Surg Oncol. 1992;18:131–134.PubMed Maehara Y, Anai H, Moriguchi S, Watanabe A, Tsujitani S, Sugimachi K. Gastric carcinoma invading muscularis propria and macroscopic appearance. Eur J Surg Oncol. 1992;18:131–134.PubMed
Metadata
Title
Is Subdivision of pT2 Tumors Superior to Lymph Node Metastasis for Predicting Survival of Patients with Gastric Cancer? Review of 224 Patients from Four Centers
Authors
Ahmet Bilici
Faysal Dane
Mesut Seker
Bala Basak Oven Ustaalioglu
Mehmet Aliustaoglu
Suleyman Temiz
Cem Gezen
Dilek Yavuzer
Gorkem Aksu
Alpaslan Mayadagli
Mahmut Gumus
Kazim Uygun
Nazim Serdar Turhal
Publication date
01-11-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1721-z

Other articles of this Issue 11/2011

Digestive Diseases and Sciences 11/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine